CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)
The purpose of this study is to investigate the relationship between the side effects(especially arthralgia and arthritis) which appear in the patients who are prescribed aromatase inhibitor(AI) and the CYP19 genetic polymorphisms.
Breast Neoplasms|Arthralgia|Arthritis|Genetic Polymorphism
DRUG: Aromatase Inhibitor(Femara or Arimidex)
Change of SNPs (PCR & sequencing), Estrogen, Inflammatory Cytokine level, 6, 12 months
EORTC (European Organization for Research and Treatment of Cancer)- QOL(Quality of Life)- C30, BR23 & Skeletal pain information, BMI, 3,6,12 months
The purpose of this study is to investigate the relationship between the side effects(especially arthralgia and arthritis) which appear in the patients who are prescribed aromatase inhibitor(AI) and the CYP19 genetic polymorphisms.